Understanding how proteins misfold and aggregate could transform approaches to neurodegenerative diseases like ALS, Alzheimer's, and Huntington's disease. The molecular switches that control when helpful proteins become harmful clumps have remained largely mysterious, limiting therapeutic development. Synthetic protein chemistry now reveals that the three-dimensional handedness of amino acids—their chirality—acts as a precise regulatory mechanism for protein aggregation in low-complexity domains. By systematically flipping specific amino acids from their natural left-handed (L) to right-handed (D) configuration, researchers identified critical geometric constraints that either promote or prevent protein self-association. These chiral inversions altered aggregation behavior without changing the chemical identity of amino acid side chains, demonstrating that spatial arrangement alone drives pathological protein clumping. The technique pinpointed specific residues where chirality acts as a molecular brake, preventing runaway aggregation that characterizes neurodegenerative conditions. This geometric precision suggests that protein aggregation operates through highly specific three-dimensional interactions rather than simple chemical attraction. The findings challenge conventional approaches to protein engineering and drug design, which typically focus on chemical modifications rather than spatial geometry. For aging adults concerned about cognitive decline, this research opens potential therapeutic avenues targeting the geometric architecture of disease-associated proteins. However, translating these synthetic biology insights into practical treatments requires significant development, as current methods remain laboratory-bound. The work represents foundational science that could eventually inform precision medicine approaches to neurodegeneration, though clinical applications remain years away.